After two giddy years of continuous growth, biotech got a rude awakening in late 2015, but many remain confident in the sector's growth potential, writes Andrew McConaghie.
Immunocore, a UK-based biotech specialising in T-cell receptor drugs has raised $320 million (£205 million), making it Europe's largest private life sciences financing.
2014 was a watershed year for companies developing gene therapy and genome editing technologies, but 2015 is shaping up to be even better, according to speakers at this week's JP Morgan hea
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
